Pharsight to Present on Its Vision for Modeling and Simulation Software at PAGE Annual Meeting
Dr. Robert Leary will discuss computational methods for model evaluation; Dr. Mike Dunlavey will present simplified programming approaches of population model user interfaces.
Mountain View, CA-June 12, 2008-Pharsight Corporation, a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Pharsight software development experts will deliver two poster presentations at the Population Approach Group in Europe (PAGE) 17th Annual Meeting in Marseille, France from June 18–20, 2008. Robert Leary, PhD, fellow, Pharsight Research and Development Group, will present work on computational methods for model evaluation. Mike Dunlavey, PhD, fellow, Pharsight Research and Development Group, will present new approaches on simplified programming of population model user interfaces.
These poster sessions will provide a forum for pharmaceutical scientists from industry and academia to have scientific discussion and collaborative exchange on model-based approaches. Pharsight's two presentations are:
• June 18: Simplified Programming of Population Model User Interfaces. Dr.
Dunlavey will present a differential execution algorithm that allows a
"painting" paradigm (called Dynamic Dialogs) as an alternative to
event-based programming. This programming paradigm simplifies
implementation of software products with complex graphical displays and
user interface requirements.
• June 19: Nonparametric Analogs to POSTHOC Estimates for Exploratory
Data Analysis. Dr. Leary will present a nonparametric model evaluation
method to complement commonly used approaches for exploratory data
analysis of possible covariate relationships. This work builds on
applied research presented by industry colleagues at past PAGE
conferences and on Dr. Leary's earlier work in the area of nonlinear
mixed effects (NLME) analysis.
"The development of advanced computational tools and next generation programming languages are integral to the continued growth of model-based drug development," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "We continue to develop technology to remain on the cutting edge of the industry and to create solutions that meet our customers' specific needs. Pharsight looks forward to presenting on specific elements of our vision for the future of model-based drug development, and is proud to again have such a wide presence at PAGE this year."
Additional information about PAGE can be found at http://www.page-meeting.org.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
